CRP and heart failure: This study aimed to evaluate the effect of sodium-glucose co-trans-porter 2 inhibitors (SGLT2i) (Dapagliflozin or Empagliflozin) on inflammation measured by C-reactive protein levels, erythrocyte sedimentation rate (ESR) and fibrinogen in patients with chronic heart failure when administered together with other standard heart failure medications.